Citius Oncology Files Q1 2025 10-Q Report
Ticker: CTOR · Form: 10-Q · Filed: May 14, 2025 · CIK: 1851484
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceuticals
TL;DR
Citius Oncology (CTZX) filed its 10-Q for Q1 2025. All good.
AI Summary
Citius Oncology, Inc. filed its 10-Q for the quarterly period ended March 31, 2025. The company, formerly known as TenX Keane Acquisition, is incorporated in Delaware and operates in the pharmaceutical preparations sector. Its principal executive offices are located in Cranford, NJ.
Why It Matters
This filing provides investors with an update on Citius Oncology's financial performance and operational status for the first quarter of 2025.
Risk Assessment
Risk Level: low — This is a standard quarterly filing with no immediate red flags or significant new disclosures.
Key Players & Entities
- CITIUS ONCOLOGY, INC. (company) — Filer
- March 31, 2025 (date) — Quarterly period end date
- TenX Keane Acquisition (company) — Former company name
- 20210315 (date) — Date of name change
- 11 Commerce Drive, First Floor, Cranford, NJ 07016 (location) — Principal executive offices address
FAQ
What is the primary business of Citius Oncology, Inc.?
Citius Oncology, Inc. operates in the Pharmaceutical Preparations sector, as indicated by its Standard Industrial Classification code [2834].
When was Citius Oncology, Inc. formerly known as?
Citius Oncology, Inc. was formerly known as TenX Keane Acquisition, with a name change effective on March 15, 2021.
Where are Citius Oncology, Inc.'s principal executive offices located?
The principal executive offices of Citius Oncology, Inc. are located at 11 Commerce Drive, First Floor, Cranford, NJ 07016.
What is the fiscal year end for Citius Oncology, Inc.?
The fiscal year end for Citius Oncology, Inc. is September 30 (0930).
What is the filing date of this 10-Q report?
This 10-Q report was filed on May 14, 2025.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding CITIUS ONCOLOGY, INC. (CTOR).